The U.S. Preventive Services Task Force (USPSTF) has issued a final recommendation statement on screening adults at increased risk for type 2 diabetes, but the American Diabetes Association (ADA) is “tremendously disappointed” in the new recommendation. The USPSTF now recommends screening for abnormal blood glucose as part of cardiovascular risk assessment in adults ages 40–70 years who are overweight or obese and referring patients with abnormal blood glucose to intensive behavioral counseling intervention to promote healthy diet and physical activity.  Since the previous recommendation in 2008, six new studies on lifestyle intervention have demonstrated the consistent benefit of lifestyle modification to prevent or delay diabetes progression. 

RELATED: T2DM Screening for At-Risk Adults Recommended by USPSTF

However, the ADA states that the new USPSTF recommendation falls short of the well-established screening guidelines of diabetes experts around the world, including those of the ADA. as well as the USPSTF’s draft recommendation, released in October 2014, in which the Task Force recommended screening all adults at increased risk.  The ADA currently recommends screening for diabetes in adults aged ≥45 years and screening in persons with multiple risk factors regardless of age. 

While the ADA acknowledges that the USPSTF recommendation to screen for abnormal blood glucose in overweight and obese individuals ages 40–70 will help identify more patients with type 2 diabetes and prediabetes than the 2008 recommendation, which listed only hypertension as a risk factor, by recommending screening solely for this patient population, the USPSTF omits populations most highly impacted by undiagnosed diabetes. In adults aged 20–44, the rate of undiagnosed diabetes is nearly 60% higher than in the adult population as a whole. The rates of undiagnosed diabetes are 61% higher in Asian Americans, 50% higher in Hispanic Americans and 33% higher in Black Americans when compared to non-Hispanic whites; the USPSTF acknowledges in its Clinical Considerations that these populations might need earlier screening, however the recommendation itself does not include these patient populations.